Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 m
Biotechnology, Pharmaceuticals, Health
2025-11-07 7:30 AM EST | BioHarvest Sciences Inc.
BioHarvest Announces Proposed Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, BioHarvest also expects to grant the underwriter a 30-day option to purchase up to an additional
Biotechnology, Pharmaceuticals, Health
2025-11-06 4:37 PM EST | BioHarvest Sciences Inc.
James Anderson Provides Update on Holdings of Myndtec Inc.
Detroit, Michigan--(Newsfile Corp. - November 6, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On November 4, 2025, the Issuer completed the seventh tranche (the "Seventh Tranche") of a private placement of units ("Units") announced on January 30, 2025. 262,027 Units
Technology, Healthcare and Hospitals, Health
2025-11-06 4:30 PM EST | James Anderson
Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% int
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-06 8:46 AM EST | Neural Therapeutics Inc.
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific a
Biotechnology, Pharmaceuticals, Health
2025-11-06 3:15 AM EST | Defence Therapeutics Inc.
Adia Nutrition Inc. Announces Transformative 2025 Milestones and Strategic Progress Toward Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - November 5, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today recaps its pivotal year-to-date achievements, marked by explosive revenue growth, strategic divestitures, and decisive steps toward full SEC reporting and a Nasdaq listing. 2025 Key Milestones Q3 Revenue Surges Over 200% Quarter-Over-Quarter: On October 8, preliminary results sh
Healthcare and Hospitals, Health
2025-11-05 10:00 AM EST | Adia Nutrition Inc.
Functional Brands Secures Direct Listing on the Nasdaq Capital Market Under the Symbol MEHA
Lake Oswego, Oregon--(Newsfile Corp. - November 5, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, announced today that it has received approval to list its shares on the Nasdaq under the symbol (NASDAQ: MEHA). The company expects its shares to commence trading today. Functional Brands Inc. is powered by Kirkman®, a legacy brand with over 75 years of trust from families and practitioners across 35+ countries. With an F
Household / Consumer / Cosmetics, Health
2025-11-05 8:00 AM EST | Functional Brands Inc.
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on Decembe
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-05 7:45 AM EST | Cardiol Therapeutics Inc.
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-05 7:00 AM EST | Conexeu Sciences Inc.
MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - November 4, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the seventh tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The seventh tranche of the private placement consists of 262,027 Units of the Company (the "Units") at a price of
Technology, Healthcare and Hospitals, Health
2025-11-04 6:00 PM EST | MyndTec Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:09 PM EST | Hemostemix Inc.
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an inve
Biotechnology, Pharmaceuticals, Health
2025-11-04 7:30 AM EST | BioHarvest Sciences Inc.
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health technology innovator specializing in nano-optic solutions that effectively block wavelengths of light linked to vision stress and degenerative eye disease, is pleased to announce the granting of its third U.S. technology patent – U.S. Patent No. 12,383,955 (B2) – further strengthening its proprietary leadership position in advanced eye-protection nano
2025-11-04 7:00 AM EST | Rise Health Nano Optics
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from its latest preclinical in vivo study evaluating Accum®-Kadcyla, a novel version of Genentech/Roche's marketed ADC Kadcyla® (ado-trastuzumab
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:15 AM EST | Defence Therapeutics Inc.
CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform
Toronto, Ontario--(Newsfile Corp. - November 4, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has terminated a royalty agreement announced October 1, 2025 (the "Royalty Agreement) and entered into a loan agreement dated November 3, 2025 (the "Loan Agreement") with current debt lenders to the Company (the "Lend
Technology, Healthcare and Hospitals, Health
2025-11-04 12:40 AM EST | CardioComm Solutions, Inc.
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device develop
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-11-03 4:30 PM EST | IR-MED, Inc.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, Januar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 1:40 PM EST | Phio Pharmaceuticals Corp.